The application of in vitro surveillance data for antibacterial dose selection

Hunter, 2002, The current status of surveillance of resistance to antimicrobial agents: report on a meeting, J Antimicrob Chemother, 49, 17, 10.1093/jac/49.1.17 Diekema, 2001, Clin Infect Dis, 32, S114, 10.1086/320184 Farrell, 2004, Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003, Antimicrob Agents Chemother, 48, 1882, 10.1128/AAC.48.5.1882-1884.2004 Felmingham, 1996, A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project, J Antimicrob Chemother, 38, 1, 10.1093/jac/38.suppl_A.1 Harrison, 1998 The Joint Commission, 2013 Jones, 2005, An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004, Diagn Microbiol Infect Dis, 53, 247, 10.1016/j.diagmicrobio.2005.10.006 Jones, 2000, In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program, Clin Infect Dis, 31, S16, 10.1086/314054 National Nosocomial Infections Surveillance S, 2004, National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004, Am J Infect Control, 32, 470, 10.1016/j.ajic.2004.10.001 Low, 2001, Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999, Clin Infect Dis, 32, S133, 10.1086/320185 Pfaller, 2001, Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program, Clin Infect Dis, 32, S156, 10.1086/320187 Sahm, 1999, Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA, Clin Infect Dis, 29, 259, 10.1086/520195 Spencer, 1997, Surveillance of the current resistance of nosocomial pathogens to antibacterials, Clin Microbiol Infect, 3, S21, 10.1111/j.1469-0691.1997.tb00644.x Lorian, 1995, The need for surveillance for antimicrobial resistance, Infect Control Hosp Epidemiol, 16, 638, 10.2307/30141116 WHO, 1978 Ambrose, 2007, Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore, Clin Infect Dis, 44, 79, 10.1086/510079 Bulik, 2013, Poster A-295 FDA, 2007 FDA, 2016 Ambrose, 2005, Poster A-1834 Jones, 2010, Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, Clin Infect Dis, 51, S81, 10.1086/653053 ICPD, 2017 CLSI, 2017 Freire, 2010, Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia, Diagn Microbiol Infect Dis, 68, 140, 10.1016/j.diagmicrobio.2010.05.012 Ambrose, 2010, Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!, Clin Infect Dis, 51, S103, 10.1086/653057 Bhavnani, 2015, Abstr. #793 Bhavnani, 2016, Poster #1976 Bhavnani, 2017, Abstr #1065 Nabriva Nabriva Therapeutics announces positive topline results from global, Phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia, 2017 http://investors.nabriva.com/phoenix.zhtml?c=254099&p=irol-newsArticle_Print&ID=2301162. September 2017. Rubino, 2010, Abstr #A1-681 Bhavnani, 2017, Abstract 63388, 4 Baxdela™, 2017 USCAST, 2017 EUCAST, 2017 USCAST Bhavnani, 2016, Abstract 57226 Flamm, 2016, Abstr. Sunday-457 Bhavnani, 2008, Abstr #994 Bhavnani, 2015, Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations, Antimicrob Agents Chemother, 60, 1600, 10.1128/AAC.02967-15 Sader, 2011, Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010), Diagn Microbiol Infect Dis, 70, 412, 10.1016/j.diagmicrobio.2011.02.008 DeRyke, 2007, Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment, Diagn Microbiol Infect Dis, 58, 337, 10.1016/j.diagmicrobio.2007.01.004 Rhomberg, 2005, Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004), J Chemother, 17, 459, 10.1179/joc.2005.17.5.459 Katsube, 2017, Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function, Antimicrob Agents Chemother, 61, 10.1128/AAC.01381-16 Ito, 2016, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, J Antimicrob Chemother, 71, 670, 10.1093/jac/dkv402 Kohira, 2016, In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains, Antimicrob Agents Chemother, 60, 729, 10.1128/AAC.01695-15 Kim, 2009, Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia, Clin Ther, 31, 2765, 10.1016/j.clinthera.2009.11.026 Koomanachai, 2010, Pharmacodynamic modeling of intravenous antibiotics against Gram-negative bacteria collected in the United States, Clin Ther, 32, 766, 10.1016/j.clinthera.2010.04.003 Melhem, 2014, Abstr. ECCMI-3975 Okusanya, 2012, Abstr #A-1269 Okusanya, 2010, Abstr #A1-692 Jones, 2009, Abstr #F1-2035 Owens, 2005, Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae, Diagn Microbiol Infect Dis, 51, 45, 10.1016/j.diagmicrobio.2004.08.019 Jones, 2003, Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team, Antimicrob Agents Chemother, 47, 292, 10.1128/AAC.47.1.292-296.2003 Van Wart, 2013, Abstr #P 914 Galani, 2012, Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece, J Chemother, 24, 191, 10.1179/1973947812Y.0000000015 Van Wart, 2014, Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae, Antimicrob Agents Chemother, 58, 885, 10.1128/AAC.01680-13 Van Wart, 2013, Abstr #A-1054c Landman, 2010, Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City, J Antimicrob Chemother, 65, 2123, 10.1093/jac/dkq278 Van Wart, 2012, Abstr #A-1961 Farrell, 2011, Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY antimicrobial surveillance program, Diagn Microbiol Infect Dis, 71, 415, 10.1016/j.diagmicrobio.2011.08.011 Zelenitsky, 2010, Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection, J Antimicrob Chemother, 65, 1725, 10.1093/jac/dkq211